- Home
- CFBK vs OBIO Comparison
CFBK vs OBIO Comparison
Compare CFBK & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- OBIO
- Stock Information
- Founded
- CFBK 1892
- OBIO 2017
- Country
- CFBK United States
- OBIO United States
- Employees
- CFBK N/A
- OBIO N/A
- Industry
- CFBK Major Banks
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- CFBK Finance
- OBIO Health Care
- Exchange
- CFBK Nasdaq
- OBIO Nasdaq
- Market Cap
- CFBK 159.5M
- OBIO 147.8M
- IPO Year
- CFBK 1998
- OBIO N/A
- Fundamental
- Price
- CFBK $25.50
- OBIO $2.73
- Analyst Decision
- CFBK Buy
- OBIO Strong Buy
- Analyst Count
- CFBK 1
- OBIO 4
- Target Price
- CFBK $29.00
- OBIO $14.00
- AVG Volume (30 Days)
- CFBK 33.1K
- OBIO 303.5K
- Earning Date
- CFBK 10-29-2025
- OBIO 08-12-2025
- Dividend Yield
- CFBK 1.29%
- OBIO N/A
- EPS Growth
- CFBK 36.66
- OBIO N/A
- EPS
- CFBK 2.77
- OBIO N/A
- Revenue
- CFBK $52,793,000.00
- OBIO $2,944,000.00
- Revenue This Year
- CFBK $39.98
- OBIO $19.83
- Revenue Next Year
- CFBK $10.47
- OBIO $12.53
- P/E Ratio
- CFBK $8.93
- OBIO N/A
- Revenue Growth
- CFBK 20.91
- OBIO 41.61
- 52 Week Low
- CFBK $19.23
- OBIO $2.37
- 52 Week High
- CFBK $31.17
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- CFBK 70.44
- OBIO 49.24
- Support Level
- CFBK $24.28
- OBIO $2.65
- Resistance Level
- CFBK $25.08
- OBIO $3.08
- Average True Range (ATR)
- CFBK 0.40
- OBIO 0.16
- MACD
- CFBK 0.03
- OBIO 0.02
- Stochastic Oscillator
- CFBK 72.67
- OBIO 50.00
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.